We assist clients at all stages of the investment cycle.
While the industry continues to bounce back following the global financial crisis, private equity and venture capital firms face new challenges in their transactions and fund structuring to ensure portfolio growth and successful exit strategies.
Our private equity team has extensive experience assisting Australian and international private equity firms to achieve their investment goals, and includes lawyers with private equity and leveraged finance experience in the UK and US.
We assist clients at all stages of the investment cycle from early stage venture capital, growth equity, right through to traditional buy out. Our expertise covers a wide range of areas including the establishment of private equity funds, development and expansion, capital investments, MBOs, LBOs and auction sale processes. We also advise on the privatisation of publicly listed companies and the acquisition of interests in existing private equity fund portfolios.
Our hands-on specialists can assist with:
Acting for BPEA Private Equity Fund VIII (“EQT”) on its acquisition of VetPartners, the leading provider of veterinary and animal health services in Australia and New Zealand (2023).
Acting for Advent on its acquisition of a majority stake in the Australian luxury fashion brand ZIMMERMANN, which operates retail stores in Australia, the US, UK, Europe and China, as well as being represented in prestigious department stores and luxury retailers worldwide (2023).
Acting for Potentia in relation to its take-private acquisition of Nitro Software (ASX:NTO), a document productivity software company, in an on–market takeover (2023), its acquisition of Micromine (2018), a mining technology company and to its portfolio acquisitions by Micromine of Precision Mining (2021) and Alastri Holdings (2021), its acquisition of SuperChoice Services (2021), its acquisition of NewBook (2021), its acquisition of Commerce Vision (2021), its portfolio acquisition of Premier Technologies, a payments solution (2020), its acquisition of 100% of PC-EFTPOS (2019) as well as its investment in Soprano Design, a communications platform as a service (CPaaS) operator (2023) and its investment in EstimateOne, a construction tech company (2021).
Acting in relation to its divestment of V8 Supercars to RACE (2021), its partial divestment of illion (formerly Dunn & Bradstreet) to Macquarie (2020) and its divestment of LCR Group to Qube Holdings (2019).
Acting in relation to its divestment of Biomedx (2023), its acquisitions of Genea Fertility (2022) and Adora (2022), its investment in Baby Village (2021), its acquisitions of Simplyai (2023) and of Melbourne IT Consulting (Seisma) (2020), and the portfolio acquisitions by Seisma of coIB (2020), Smart Apps (2021), Braestone (2021) and Data Addiction (2023), and the portfolio acquisition by Genea Fertility of Fertility SA (2023).
Acting for HumanForce, an Accel-KKR portfolio company, on its acquisition of IntelliHRLimited (ASX:IHR), an HR software platform, by way of scheme of arrangement and subsequently by way of a contested takeover bid (2023).
Advised on its acquisition of RM Williams (2013); advised on its acquisition of Seafolly (2014); advised on its acquisition of 2XU (2013).
Advised on its acquisition of Linktree (2020); advised on its acquisition of Kumo Holdings (2020); advised on the sale of GCC to Virgin Pulse (an Insight portfolio company) (2016); advised on its acquisition of Campaign Monitor (2014).
Advised on the sale by TJS Services to Anchorage Capital Partners (2017).
Advised on its proposed indirect acquisition of 80% of the securities of OAC Group (2018) and advised Virgin Group on its co-investment in the Bain consortium bid into Virgin Australia airlines (2020).
Advised on the acquisition of stake in Learnosity (2018); advised on the acquisition of PageUp from its founders, Accel-KKR Growth Capital Partners and Accel-KKR Members Fund (2019).
Advised on Australian aspects of its acquisition of Emergent Cold as well as its acquisition of five cold storage facilities from Blackstone (2020) .
Advised on its acquisition of ENE.HUB (2018).
Advised on its acquisition of Serraview Holdings (2018).
Advised on its acquisition of HotSchedules (formerly RedBook) (2019).
Advised on its PIPE investment into Afterpay (ASX:APT) (2018).
Advised on the acquisition of Pharmaceutical Packaging by PCI Pharma (a Partners portfolio company) (2018).
Advised on the sale by Canberra Data Centres to Quadrant (2014).
Advised on the sale by Macquarie Group of its private markets business to ROC Partners (2014).
Advised on its acquisition of Tasmanian Alkaloids (2016).
This week marks a significant development in Australia’s privacy law reform process, which is likely to result in some changes becoming law before the next federal election.
The European Commission recently fined a large global pharmaceutical company €462.6 million for abusing its dominant position to lessen competition in the market for the supply of Copaxone...
The past year has undoubtedly been challenging for companies in the lithium, rare earth and critical minerals sectors. To provide some context, lithium carbonate, lithium hydroxide and spodumene...
Recent cases have highlighted whether an ASX-listed entity must make a market disclosure to the ASX if it receives a confidential compulsory investigation notice under section 155 of the...